admin The US Food and Drug Administration is all set to put into consideration a new drug for the Alzheimer’s disease after a wait of nearly twenty years. The agency is all set to meet for the discussion of the new drug aducanumab which will be an experimental treatment that will work through intravenous infusion after the early detection of the Alzheimer’s disease in patients.
The agency will decide whether or not to recommend this way and drug for the treatment. A committee will sit to advise the FDA on the same issue but they are only entitled to an advice and not the final say or decision in the matter.
This committee will sure have a significant impact on the final decision of the FDA. The agency is no hurry however to approve or disapprove the drug. It will first thoroughly go through the impacts and the possible improvement that this drug has to offer to the patients and then come out with the final one. If satisfied only then will they deliver a final judgement which could be delayed up to next year as well.
The committee earlier this week posted a 343 long document online on the website about the discussions that took place where a little inclination towards the support of the drug is visible. Although to clearly say which side the committee is leaning towards is a little difficult to infer from the given document.
The future treatment that is likely to benefit the patients is that of providing them an early treatment by detecting the disease at the earliest stage possible. If the drug does get approved another significant concern that the FDA faces is that of the pricing of the same making sure that the drug is feasible to most patients.
A lot of speculation is being made at the moment and every scientist and researcher has a different opinion regarding whether or not the drug aducanumab should be approved.
What the final decision would be is almost impossible to predict at the moment, according to a Issacson, a leading researcher it is a watershed moment in the field.
Magazine 
